<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35245941</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls.</ArticleTitle><Pagination><StartPage>e962</StartPage><EndPage>e973</EndPage><MedlinePgn>e962-e973</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ciac151</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac151</ELocationID><Abstract><AbstractText Label="BACKGROUND">We aimed to quantify the unknown losses in health-related quality of life of coronavirus disease 2019 (COVID-19) cases using quality-adjusted lifedays (QALDs) and the recommended EQ-5D instrument in England.</AbstractText><AbstractText Label="METHODS">Prospective cohort study of nonhospitalized, polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2-positive (SARS-CoV-2-positive) cases aged 12-85 years and followed up for 6 months from 1 December 2020, with cross-sectional comparison to SARS-CoV-2-negative controls. Main outcomes were QALD losses; physical symptoms; and COVID-19-related private expenditures. We analyzed results using multivariable regressions with post hoc weighting by age and sex, and conditional logistic regressions for the association of each symptom and EQ-5D limitation on cases and controls.</AbstractText><AbstractText Label="RESULTS">Of 548 cases (mean age 41.1 years; 61.5% female), 16.8% reported physical symptoms at month 6 (most frequently extreme tiredness, headache, loss of taste and/or smell, and shortness of breath). Cases reported more limitations with doing usual activities than controls. Almost half of cases spent a mean of &#xa3;18.1 on nonprescription drugs (median: &#xa3;10.0), and 52.7% missed work or school for a mean of 12 days (median: 10). On average, all cases lost 13.7 (95% confidence interval [CI]: 9.7, 17.7) QALDs, whereas those reporting symptoms at month 6 lost 32.9 (95% CI: 24.5, 37.6) QALDs. Losses also increased with older age. Cumulatively, the health loss from morbidity contributes at least 18% of the total COVID-19-related disease burden in the England.</AbstractText><AbstractText Label="CONCLUSIONS">One in 6 cases report ongoing symptoms at 6 months, and 10% report prolonged loss of function compared to pre-COVID-19 baselines. A marked health burden was observed among older COVID-19 cases and those with persistent physical symptoms.</AbstractText><CopyrightInformation>&#xa9; Crown copyright 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandmann</LastName><ForeName>Frank G</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0001-5641-1931</Identifier><AffiliationInfo><Affiliation>Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tessier</LastName><ForeName>Elise</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2712-7971</Identifier><AffiliationInfo><Affiliation>Immunisation Division, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>COVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacy</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2063-1443</Identifier><AffiliationInfo><Affiliation>Immunisation Division, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kall</LastName><ForeName>Meaghan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6971-427X</Identifier><AffiliationInfo><Affiliation>COVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Leeuwen</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2383-5305</Identifier><AffiliationInfo><Affiliation>Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charlett</LastName><ForeName>Andre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7154-0432</Identifier><AffiliationInfo><Affiliation>Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggo</LastName><ForeName>Rosalind M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-0362-6717</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabrera</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4606-5945</Identifier><AffiliationInfo><Affiliation>COVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmunds</LastName><ForeName>W John</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-9179-2917</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7156-7640</Identifier><AffiliationInfo><Affiliation>Immunisation Division, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9840-8917</Identifier><AffiliationInfo><Affiliation>Immunisation Division, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amirthalingam</LastName><ForeName>Gayatri</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2078-0975</Identifier><AffiliationInfo><Affiliation>Immunisation Division, UK Health Security Agency, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jit</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6658-8255</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">19</Keyword><Keyword MajorTopicYN="N">2</Keyword><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">CoV</Keyword><Keyword MajorTopicYN="N">QALYs</Keyword><Keyword MajorTopicYN="N">SARS</Keyword><Keyword MajorTopicYN="N">health</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">related quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35245941</ArticleId><ArticleId IdType="pmc">PMC8903473</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac151</ArticleId><ArticleId IdType="pii">6542727</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>